Abstract
Myostatin is a negative regulator of muscle mass. Important advances in our understanding of thecomplex biology of this factor have revealed the therapeutic potential of antagonizing the myostatin pathway. Herewe present the rationale for evaluating anti-myostatin therapies in human muscle-wasting disorders.
Keywords: Myostatin, Muscle, Adipose tissue, Rhabdomyosarcoma, Myostatin antagonism, Myostatin processing and signaling, therapeutic approaches
Mini-Reviews in Medicinal Chemistry
Title: Myostatin: Biology and Clinical Relevance
Volume: 6 Issue: 7
Author(s): Gilles Carnac, Stephanie Ricaud, Barbara Vernus and Anne Bonnieu
Affiliation:
Keywords: Myostatin, Muscle, Adipose tissue, Rhabdomyosarcoma, Myostatin antagonism, Myostatin processing and signaling, therapeutic approaches
Abstract: Myostatin is a negative regulator of muscle mass. Important advances in our understanding of thecomplex biology of this factor have revealed the therapeutic potential of antagonizing the myostatin pathway. Herewe present the rationale for evaluating anti-myostatin therapies in human muscle-wasting disorders.
Export Options
About this article
Cite this article as:
Carnac Gilles, Ricaud Stephanie, Vernus Barbara and Bonnieu Anne, Myostatin: Biology and Clinical Relevance, Mini-Reviews in Medicinal Chemistry 2006; 6 (7) . https://dx.doi.org/10.2174/138955706777698642
DOI https://dx.doi.org/10.2174/138955706777698642 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
p73 as a Pharmaceutical Target for Cancer Therapy
Current Pharmaceutical Design Anti-Viral
Current Bioactive Compounds The Neuroendocrine Component in Bladder Tumors
Current Medicinal Chemistry Poly (D,L-lactic-co-glycolide) Nanoparticles for the Improved Therapeutic Efficacy of All-trans-retinoic Acid: A Study of Acute Myeloid Leukemia (AML) Cell Differentiation In Vitro
Medicinal Chemistry Combination of DC Vaccine and Conventional Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry Potassium Channels are a New Target Field in Anticancer Drug Design
Recent Patents on Anti-Cancer Drug Discovery Tropism-Modified Adenoviral and Adeno-Associated Viral Vectors for Gene Therapy
Current Gene Therapy Lifestyle Factors and MicroRNAs: A New Paradigm in Cancer Chemoprevention
MicroRNA Genetic Predisposition to Neonatal Tumors
Current Pediatric Reviews Anti-Inflammatory and Anti-Neoplastic Actions of Resveratrol
Current Nutrition & Food Science Electrochemotherapy as First Line Cancer Treatment: Experiences from Veterinary Medicine in Developing Novel Protocols
Current Cancer Drug Targets Contrast Media in Cardiovascular Magnetic Resonance
Current Pharmaceutical Design Targeting the Plasmodium Ubiquitin/Proteasome System with Anti- Malarial Compounds: Promises for the Future
Infectious Disorders - Drug Targets The Synergistic Effects of DNA-Targeted Chemotherapeutics and Histone Deacetylase Inhibitors As Therapeutic Strategies for Cancer Treatment
Current Medicinal Chemistry Integrins in Bone Metastasis Formation and Potential Therapeutic Implications
Current Cancer Drug Targets Targeting FoxO1 for Hypertriglyceridemia
Current Drug Targets Aflibercept: A Novel VEGF Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Tumors
Mini-Reviews in Medicinal Chemistry Need to Think Outside Organ-based Diagnosis to Molecular Diagnostics
Applied Clinical Research, Clinical Trials and Regulatory Affairs From French Paradox to Cancer Treatment: Anti-cancer Activities and Mechanisms of Resveratrol
Anti-Cancer Agents in Medicinal Chemistry Oncotarget Strategies For Herpes Simplex Virus-1
Current Gene Therapy